Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 1996

View Archived Issues

Ethical's sustained-release morphine sublicensed for Canada

Antimicrobial peptide combinations available for licensing

Methods for screening for neurotoxicity offered for licensing

Frog peptides with antimicrobial activity available for licensing

Novel porphycene compounds synthesized at Cytopharm

Dual-action PDE IV/TNF-alpha inhibitors reported by Janssen

Lilly research into antiobesity proteins continues

Therapeutically active NPY analogues reported by Salk Institute

Antihyperlipidemic agents from natural source described by Takeda

Potent ACAT inhibitor discovered by Kitasato Institute

Antiproliferative agents disclosed by Kitasato Institute

New anxiolytic under development at Parke-Davis

Antiepileptic agent reported by Parke-Davis

Merck & Co. describes lipid A biosynthesis inhibitor with antibacterial activity

Axcan-Schwarz joint venture to market URSO

Ivermectin approved for use in humans

SuperGen-Galenica anticancer drug collaboration

Expanded patent portfolio for Dyax technology

Lidak reacquires certain rights to Lidakol from BMS

Antiepileptic drug from Neurogen licensed to Wyeth-Ayerst

Patent issued for method of diagnosing and treating impotence

Incyte-Affymetrix to develop and commercialize new chip-based genomic databases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...